BIC BECKER INTERMEDIATES CATALOGUE

Global Intermediates and Active Ingredients Database Providing Comprehensive Life Science Chemistry

WHO WILL BENEFIT

Key Decision Makers

Business Development Directors

- > Pharmaceutical Marketing Directors
- > Intermediates Producers
- > Purchasing & Procurement Managers
- > Import & Export Managers
- > Marketing Directors & Managers
- > Pharmaceutical Supply Managers
- > Pharmaceutical Research & Development Directors
- > Quality Assurance Directors
- > Logistics Managers
- > Agrochemical Research & Development Directors & Managers
- > Veterinary Research & Development Directors & Managers

TIME SAVING FEATURES & BENEFITS

Using the BIC

> Search text data and structure separately or at the same time

> Open exports with a web browser, Microsoft Word, or any other text processor, Acrobat or send by email

- > Export selected data to Excel, or any other spreadsheet program
- > Retrieve chemical structures in a ChemDraw, molfile or jpeg file
- > Store selected data into folders for further use and processing

KEY FEATURES

The BIC covers active ingredients and key intermediates related to Life Science:

> Profiles over 24,500 active ingredients, pharmaceuticals, diagnostic aids, food additives, agrochemicals, and pesticides from discovery phases to launch

- > Includes patent information and synthesis of molecules in preclinical, clinical, and launched phase molecules
- > Over 10,300 molecules with fully analyzed routes starting from basic commodities
- > Links active ingredients to technologies, named reactions, reagents, catalysts, and chemical classes
- > Provides necessary chemistry to non-infringing routes

The BIC helps you gain insight into the Life Science market:

> Discover the pipeline of any pharmaceutical company

- > Links intermediates & fine chemicals to active ingredients, which gives you intelligence regarding business opportunities
- > Identify key intermediates among 61,000 fine-chemicals and commodities
- > Extensive patent and scientific coverage



"The BIC is an efficient working tool which we use to very quickly identify existing commercial products and check the technology synthesis at a first glance. For me it is important that a database is very fast - which the BIC-is. With its searching tools (query language), I can sort out almost everything I want. It is important for anyone in the fine chemical industry to have quick access to all major pharma and agro products and to have a database which is updated frequently. There are many very useful features (eg. Classify Tool) which anyone can use to minimize time in future searches."

G.H., Director New Products, Alzchem

SUBSCRIBER ADVANTAGES

- > Exclusive access to novel competitive production processes
- > Custom analysis of chemical data and patents
- > Receive 8 hours of FREE consulting service
- > FREE training and technical support on database operations

> Also includes above 7500+, launched, OTC, reagents, orphan drug active ingredients

AVAILABLE FORMATS

Online access as single user accounts, updated daily



sales@beckerdata.com





S566 Main Street, Suite 206 Frisco, TX 75033, U.S.A

https://beckerdata.com



Product	Lapatinib				
Nomenclature	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2- (methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine				
Chemical Class	Quinazoline				
Other Names	Lapatinib Ditosylate (USAN) ; Lapatinib ditosylate monohydrate				
Development Code	GW-572016 ; GW572016 ; GW-2016 ; GW2016 ; GW-572016F ; GW572016F ; GSK-572016 ; GSK572016 ; 572016				
CAS Number	231277-92-2 ; 388082-78-8 (ditosylate monohydrate)				
General Formula	C29H26ClFN4O4S				
Molecular Weight	581.1				
Originator	GlaxoSmithKline (GSK)				
Developer	GlaxoSmithKline (GSK)				
Uses	Antineoplastic				
Market Status	Launched				
Launching Date	2007				
Brand	Tyverb (GSK: EU) Tykerb (GSK: USA)				
Biological Class	Cytotoxic ; Apoptotic ; Antiproliferative				
Activity Index	HER-2 (ErbB-2) and epidermal growth factor receptor (EGFR) dual kinase inhibitor				
Original Patent	Bicyclic Heteroaromatic Compounds As Protein Tyrosine Kinase Inhibit WO9935146A1 (1999) Priority: GB19980000569, 12 Jan. 1998 (Glaxo Group Ltd, GB)				
Priority Date	1998				
Polymorph Patent	US8252805 ; US8435752 ; WO2008088861A2 ; WO2008088861A3 ; WO2009137714A2 ; WO2009137714A2 ; WO2009137714A3 ;				

Reaction steps (sequence) in Tucidinostat process

Process A (US20080039509, Shenzhen Chipscreen Bioscience, China)



Intermediates used to produce Amrubicin							
FUTURE GENERICS Everything on life Science + + HOME Welcome Simple search Multiple search Substructure search Folders News							
HOME > Simple search > Results (short list) > Results (long list) > Mont (aph > Download monograph (pdf) Current folder:	Back to Longlist						
	ket Status						
INTERMEDIATE 49 result(s)	CAS Num						
I 1,4-benzoquinone II 2-ethoxy-1,3-butadiene III 6-ethoxy-1,4,a,5,8,8a-hexahydro-1,4-naphthalenedione IV sodium ethoxide V iodomethane	106-51-4 141-52-6 74-88-4						
VI 2-ethoxy-5,8-dimethoxy-1,4-dihydronaphthalene VII 5,8-dimethoxy-3,4-dihydro-2(1H)-naphthalenone VIII potassium cyanide VII ammonium carbonate IX ammonium carbonate							
X spiro[1,2,3,4-tetrahydro-5,8-dimethoxynaphthalene-2,4-hydantoin] XI 2-amino-1,2,3,4-tetrahydro-5,8-dimethoxy-2-naphthalenecarboxylic acid XII acetic anhydride	108-24-7						



	Search almost 2,000 technologies
	thing on life Science + + + <u>search</u> Substructure search Folders <u>News</u>
SEARCH on Product Clear search	h Search options
Product I Recipes Reference Polated I Technolo	- Some attributes has lists of values.

FUTURE GENERICS Everything on life Science + + + HOME Welcome Simple search Multiple search Substructure search Folders News							
<u>HOME</u> > <u>Simple search</u> > <u>Results (short list)</u> > Find over 1,000 active ingredients that use esterification in their production							
PRODUCT 1082 result(s) Export list (displayed results) See all results							
Product	CAS Number	Originator	Market Status	Uses			
(+)-YW-391		Panorama Research	Preclinical	Antineoplastic			
(+)-YW-392		Panorama Research	Preclinical	Antineoplastic			
(S)-Desmethylzopiclone	151776-26-0	Sumitomo Dainippon Pharma	Discontinued	Anxiolytic			
1'-EpiGemcitabine	122111-05-1	CHEMAGIS LTD	Reagent	Antineoplastic			
1'-EpiGemcitabine 3',5'-Dibenzoate	134790-40-2	PRIME EUROPEAN THERAPEUTICALS S.P.A,	Reagent	Antineoplastic			
18F-EF5	152721-37-4		Phase 2	Radioprotectant ; Diagnostic aid			
2-m-Hydroxy paclitaxel	132160-31-7		Reagent	Antineoplastic			
3'-EpiGemcitabine	103882-85-5	CHEMAGIS LTD	Reagent	Antineoplastic			
3'-para-Hydroxypaclitaxel	132160-32-8		Reagent	Antineoplastic			
3-Hydroxymethyl-DCK		Panacos Pharmaceuticals	Preclinical	Antiviral			

Search the BIC/FGD by structure/sub-structure

 FUTURE GENERICS
 Everything on life Science
 +

 HOME
 Welcome
 Simple search
 Multiple search
 Substructure
 Folders
 News

 HOME
 >
 Substructure
 search
 >
 Substructure
 Substructure<

Selected mode3: Any browsing software with Java / ipt ; Online structure drawing App

Procedure:

Step 1: Draw the chemical structure or import a mol file (Menu File / Open)



Step 2: Select the search target:
Active Ingredient /
Intermediate /
Both

Step 3: Click on Launch search

Search APIs by market status **GENERICS** Everything on life Science + + + Simple search Multiple search Substructure search Fold News earch > Market: Phase III roduct Clear search Search options Attributes Market Stat > Results [47] **General Formula** 15893 L /gin with 1 - / 1 <u>Ok</u> High Potency 1 Phase IID/IIIa - 1-1--Phase III Market Status <u>47</u> Phase IV Preclinical Nomenclature Preclinical (2000) Originator 7705 Preclinical (inhaled) 10601 Other Names Between each query's attribute, use this operator : and O or O but

FUTURE GENERICS Everything on life Science + + + HOME Welcome Simple search Multiple search Substructure search Folders News Uncover and discover the pipeline of HOME > Simple search > Results (short list) > any pharmaceutical company **PRODUCT** 546 result(s) Export list (displayed results) See all results CAS Number arket Status Novartis Pharma AG Antineoplastic ; Radioligand 177Lu-Satoreotide tetraxetan Phase 1 4-demethylepothilone B Novartis Preclinical Antineoplastic 5-CNAC 204852-67-5 Novartis AG Launched Anti-osteoarthritis 68Ga-satoreotide trizoxetan Novartis Pharma AG Phase 2 ; Orphan Drug Status Diagnostic Imaging ; Radioligand 8-Amino-9-benzyl-guanine 100890-94-6 Ciba-Geigy (Novartis) discontinued Antineoplastic 189758-25-6 90Y-Edotreotide Phase 2 ; Orphan Drug Status Antineoplastic Novartis 1166227-08-2 Novartis AG Preclinical Antineoplastic A-66 A-dmDT390-bisFv(UCHT1) Government of the USA (US) ; Novartis AG (Switzerland) Phase 1/2 Antineoplastic AAL-993 Novartis Pharma ; Schering AG Preclinical Antineoplastic ABN-912 Novartis discontinued Antirheumatic ; Anti-arthritic